MC-3001
/ MaxoCore
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 14, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
(PubMed, Leukemia)
- "Restricted to patients with deletions/alterations in TP53, ibrutinib appeared to abrogate the deleterious impact on outcome. These data illustrate the potential to perform a molecular analysis of predictive biomarkers on routine patient samples that can meaningfully inform clinical practice."
Journal • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • BIRC3 • CCND1 • MYC • TP53
1 to 1
Of
1
Go to page
1